58 related articles for article (PubMed ID: 38480789)
1. LINC01589 serves as a potential tumor-suppressor and immune-related biomarker in endometrial cancer: A review.
Chen R; An J; Wang Y; Yang L; Lin Q; Wang Y
Medicine (Baltimore); 2023 Apr; 102(15):e33536. PubMed ID: 37058060
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis and experimental validation of TK1 in uterine corpus endometrial carcinoma.
Sun Y; Zhang K; Wang T; Zhao S; Gao C; Xue F; Wang Y
Sci Rep; 2024 Mar; 14(1):6134. PubMed ID: 38480789
[TBL] [Abstract][Full Text] [Related]
3. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
5. Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
Zhang C; Wang R; Li M; Yang Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052291
[TBL] [Abstract][Full Text] [Related]
6. PHF6 promotes the progression of endometrial carcinoma by increasing cancer cells growth and decreasing T-cell infiltration.
Wang X; Fang A; Peng Y; Yu J; Yu C; Xie J; Zheng Y; Song L; Li P; Li J; Kang X; Lin Y; Li W
J Cell Mol Med; 2023 Mar; 27(5):609-621. PubMed ID: 36756714
[TBL] [Abstract][Full Text] [Related]
7. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
Tian Y; Wen F; Wang S; Lv N
Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
[TBL] [Abstract][Full Text] [Related]
8. A self-supervised classification model for endometrial diseases.
Fang Y; Wei Y; Liu X; Qin L; Gao Y; Yu Z; Xu X; Cha G; Zhu X; Wang X; Xu L; Cao L; Chen X; Jiang H; Zhang C; Zhou Y; Zhu J
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17855-17863. PubMed ID: 37947870
[TBL] [Abstract][Full Text] [Related]
9. Thymidine kinase 1 appears to be a marker for the prognosis of hepatocellular carcinoma based on a large-scale, multicenter study.
Jiang Y; Guo L; Han L; Li H; Li C; Wen L; Song Y; Wang Z; Wang P; Guo Q; Zhao W; Liu M; Chen J; Wu Z; Yan Y; Xu K; Gu T; Wu X; He K; Su K; Han Y
J Cancer Res Clin Oncol; 2023 Nov; 149(15):14271-14282. PubMed ID: 37561208
[TBL] [Abstract][Full Text] [Related]
10. Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners.
Li Q; Zhang L; Yang Q; Li M; Pan X; Xu J; Zhong C; Yao F; Zhang R; Zhou S; Dai X; Shi X; Dai Y; Xu J; Cheng X; Xiao W; She Z; Wang K; Qian X; Pu L; Zhang P; Wang X
Cell Metab; 2023 Jun; 35(6):912-927.e7. PubMed ID: 37071992
[TBL] [Abstract][Full Text] [Related]
11. Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Malorni L; Bianchini G; Caputo R; Zambelli A; Puglisi F; Bianchi GV; Del Mastro L; Paris I; Montemurro F; Allegrini G; Colleoni M; Tamberi S; Zamagni C; Cazzaniga ME; Orditura M; Guarneri V; Castelletti D; Benelli M; Di Marino M; Arpino G; De Laurentiis M
Eur J Cancer; 2023 Jun; 186():1-11. PubMed ID: 37003098
[TBL] [Abstract][Full Text] [Related]
12. Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer.
Tribukait B; Lundgren PO; Kjellman A; Norming U; Nyman CR; Jagarlmundi K; Gustafsson O
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982234
[TBL] [Abstract][Full Text] [Related]
13. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
de Visser KE; Joyce JA
Cancer Cell; 2023 Mar; 41(3):374-403. PubMed ID: 36917948
[TBL] [Abstract][Full Text] [Related]
14. A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer.
Cviič D; Jagarlamudi K; Meglič L; Škof E; Zore A; Lukanović D; Eriksson S; Osredkar J
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900385
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
